Pieris begins Phase I of PRS-343 in solid tumors

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) began a Phase I trial to evaluate PRS-343 in patients with advanced or metastatic HER2-positive solid tumors for whom standard treatment options are not available, no longer effective, or not tolerated, and in patients who refused standard therapy.

The open-label, dose-escalation study will evaluate safety and anti-cancer activity...